At Kleresca®, we aspire to change the fundamentals of dermatology. Our innovative biophotonic technology represents a unique mode of action that allows us to create a new gold standard within the industry for the benefit of patients worldwide. The Kleresca® biophotonic platform offers non-invasive treatments for both therapeutic and aesthetic conditions using fluorescent light energy (FLE) to stimulate the skin’s own biological processes and repair mechanisms through photobiomodulation (PBM). Demonstrating high safety and efficacy, our technology triggers documented skin repairing benefits for a number of diseases and conditions. The company is headquartered in Dublin, Ireland, and builds on the scientific heritage from LEO Pharma and KLOX Technologies. Kleresca® is currently developing ten (10) markets including Australia, Italy, Spain, France, Switzerland, Germany, Belgium, Denmark, Norway and UK. Kleresca® is also registered as FB Dermatology.